- Home
- VTAK vs BDRX Comparison
VTAK vs BDRX Comparison
Compare VTAK & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTAK
- BDRX
- Stock Information
- Founded
- VTAK 2002
- BDRX 2000
- Country
- VTAK United States
- BDRX United Kingdom
- Employees
- VTAK N/A
- BDRX N/A
- Industry
- VTAK Medical/Dental Instruments
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- VTAK Health Care
- BDRX Health Care
- Exchange
- VTAK Nasdaq
- BDRX Nasdaq
- Market Cap
- VTAK 3.1M
- BDRX 3.6M
- IPO Year
- VTAK 2018
- BDRX N/A
- Fundamental
- Price
- VTAK $0.18
- BDRX $1.07
- Analyst Decision
- VTAK
- BDRX
- Analyst Count
- VTAK 0
- BDRX 0
- Target Price
- VTAK N/A
- BDRX N/A
- AVG Volume (30 Days)
- VTAK 1.4M
- BDRX 3.5M
- Earning Date
- VTAK 05-14-2025
- BDRX 06-10-2025
- Dividend Yield
- VTAK N/A
- BDRX N/A
- EPS Growth
- VTAK N/A
- BDRX N/A
- EPS
- VTAK N/A
- BDRX N/A
- Revenue
- VTAK $481,000.00
- BDRX N/A
- Revenue This Year
- VTAK $822.86
- BDRX N/A
- Revenue Next Year
- VTAK $168.42
- BDRX N/A
- P/E Ratio
- VTAK N/A
- BDRX N/A
- Revenue Growth
- VTAK 9.57
- BDRX N/A
- 52 Week Low
- VTAK $0.16
- BDRX $1.01
- 52 Week High
- VTAK $8.40
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- VTAK 32.34
- BDRX 34.95
- Support Level
- VTAK $0.17
- BDRX $1.01
- Resistance Level
- VTAK $0.21
- BDRX $1.93
- Average True Range (ATR)
- VTAK 0.03
- BDRX 0.12
- MACD
- VTAK -0.01
- BDRX -0.01
- Stochastic Oscillator
- VTAK 13.76
- BDRX 8.67
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.